Assessing anti-inflammatory and neutrophil-modulating capacity of phage therapy for Pseudomonas aeruginosa infection - Copy of 2022/GR001499

Project Details

StatusActive
Effective start/end date3/06/23 → 3/06/25

Funding

  • Vertex: A$36,000.00
  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$144,000.00